New Zealand markets closed

Spruce Biosciences, Inc. (SPRB)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
2.9100-0.1300 (-4.28%)
At close: 04:00PM EST
3.0100 +0.10 (+3.44%)
After hours: 05:13PM EST
Full screen
Trade prices are not sourced from all markets
Previous close3.0400
Open3.0550
Bid2.5200 x 1200
Ask3.0900 x 800
Day's range2.8041 - 3.1800
52-week range0.9550 - 3.3800
Volume141,243
Avg. volume1,477,398
Market cap68.56M
Beta (5Y monthly)1.19
PE ratio (TTM)N/A
EPS (TTM)-1.8860
Earnings date13 Mar 2023 - 17 Mar 2023
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est8.29
  • Business Wire

    Spruce Biosciences to Participate in the SVB Securities Global Biopharma Conference

    SOUTH SAN FRANCISCO, Calif., February 01, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today announced that Javier Szwarcberg, M.D., M.P.H., Chief Executive Officer, will present at the SVB Securities Global Biopharma Conference on February 15, 2023, at 2:20 p.m. ET.

  • Zacks

    Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?

    When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

  • Business Wire

    Spruce Biosciences Provides Clinical Program Updates and Outlines Anticipated Milestones for 2023

    SOUTH SAN FRANCISCO, Calif., January 09, 2023--Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for rare endocrine disorders with significant unmet medical need, today provided an update on its clinical programs, anticipated upcoming milestones and strategic priorities for advancing tildacerfont in classic congenital adrenal hyperplasia (CAH) and polycystic ovary syndrome (PCOS).